Apellis Pharmaceuticals, Inc. $APLS Position Increased by Rhenman & Partners Asset Management AB

Rhenman & Partners Asset Management AB raised its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 230.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 93,250 shares of the company’s stock after purchasing an additional 65,000 shares during the quarter. Rhenman & Partners Asset Management AB owned approximately 0.07% of Apellis Pharmaceuticals worth $1,614,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Envestnet Asset Management Inc. grew its stake in shares of Apellis Pharmaceuticals by 56.4% in the 1st quarter. Envestnet Asset Management Inc. now owns 43,717 shares of the company’s stock valued at $956,000 after buying an additional 15,766 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Apellis Pharmaceuticals during the 1st quarter valued at $353,000. Assetmark Inc. lifted its stake in shares of Apellis Pharmaceuticals by 3,938.7% in the 1st quarter. Assetmark Inc. now owns 1,252 shares of the company’s stock valued at $27,000 after purchasing an additional 1,221 shares during the last quarter. Mackenzie Financial Corp lifted its stake in shares of Apellis Pharmaceuticals by 14.2% in the 1st quarter. Mackenzie Financial Corp now owns 41,533 shares of the company’s stock valued at $908,000 after purchasing an additional 5,175 shares during the last quarter. Finally, ING Groep NV acquired a new position in Apellis Pharmaceuticals during the first quarter worth $4,028,000. 96.29% of the stock is owned by hedge funds and other institutional investors.

Apellis Pharmaceuticals Stock Up 4.3%

NASDAQ APLS opened at $21.00 on Wednesday. Apellis Pharmaceuticals, Inc. has a twelve month low of $16.10 and a twelve month high of $35.72. The stock has a market cap of $2.66 billion, a PE ratio of 67.74 and a beta of 0.70. The firm has a 50-day simple moving average of $23.12 and a 200 day simple moving average of $21.92. The company has a debt-to-equity ratio of 0.90, a quick ratio of 3.10 and a current ratio of 3.54.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings data on Thursday, October 30th. The company reported $1.67 EPS for the quarter, topping analysts’ consensus estimates of $1.03 by $0.64. Apellis Pharmaceuticals had a return on equity of 18.94% and a net margin of 4.43%.The company had revenue of $458.58 million during the quarter, compared to the consensus estimate of $364.58 million. During the same quarter last year, the company earned ($0.46) EPS. The company’s quarterly revenue was up 133.0% on a year-over-year basis. On average, research analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analyst Ratings Changes

APLS has been the subject of several analyst reports. JPMorgan Chase & Co. reduced their target price on Apellis Pharmaceuticals from $40.00 to $36.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. Cantor Fitzgerald raised their target price on shares of Apellis Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a research note on Friday, August 1st. TD Cowen cut their target price on shares of Apellis Pharmaceuticals from $50.00 to $45.00 and set a “buy” rating for the company in a research report on Friday, October 31st. The Goldman Sachs Group cut shares of Apellis Pharmaceuticals from a “neutral” rating to a “sell” rating and decreased their price target for the company from $26.00 to $18.00 in a report on Friday, September 26th. Finally, Citigroup dropped their price objective on Apellis Pharmaceuticals from $52.00 to $45.00 and set a “buy” rating on the stock in a research note on Friday, October 31st. Nine equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $33.06.

Insider Buying and Selling at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, CEO Cedric Francois sold 49,963 shares of the business’s stock in a transaction on Thursday, August 28th. The shares were sold at an average price of $28.39, for a total value of $1,418,449.57. Following the sale, the chief executive officer owned 307,946 shares of the company’s stock, valued at $8,742,586.94. The trade was a 13.96% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, General Counsel David O. Watson sold 5,000 shares of the firm’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $20.06, for a total transaction of $100,300.00. Following the transaction, the general counsel directly owned 108,730 shares of the company’s stock, valued at $2,181,123.80. The trade was a 4.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 137,884 shares of company stock worth $3,517,873 over the last three months. 6.80% of the stock is currently owned by corporate insiders.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).